Form 8-K - Current report:
SEC Accession No. 0001193125-25-133730
Filing Date
2025-06-03
Accepted
2025-06-03 06:36:50
Documents
13
Period of Report
2025-06-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d869940d8k.htm   iXBRL 8-K 30119
2 EX-10.1 d869940dex101.htm EX-10.1 316973
  Complete submission text file 0001193125-25-133730.txt   546702

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vera-20250602.xsd EX-101.SCH 2835
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vera-20250602_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vera-20250602_pre.xml EX-101.PRE 11251
15 EXTRACTED XBRL INSTANCE DOCUMENT d869940d8k_htm.xml XML 3658
Mailing Address 2000 SIERRA POINT PARKWAY, SUITE 1200 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY, SUITE 1200 BRISBANE CA 94005 650-770-0077
Vera Therapeutics, Inc. (Filer) CIK: 0001831828 (see all company filings)

EIN.: 812744449 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40407 | Film No.: 251017110
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)